RASis, SGLT2is and GLP-1RAs were used by 309 (74.5%), 197 (47.5%) and 154 (37.1%) participants, respectively; 375 (90.4%), 372 (89.6%) and 338 (81.4%) participants received T2D treatment including insulin and analogues, blood pressure control and lipid modification, respectively. The gene discussed is INS; the disease is type 2 diabetes mellitus.